UroGen Pharma Ltd. — Director's Dealing 2020

Oct 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2020-10-15

Reporting Person: PFREUNDSCHUH PETER P. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-10-15	Ordinary Shares	M	4917	—	Acquired	12805	Direct
2020-10-15	Ordinary Shares	S	976	$21.7992	Disposed	11829	Direct
2020-10-15	Ordinary Shares	S	407	$21.8243	Disposed	11422	Direct
2020-10-15	Ordinary Shares	S	1017	$21.72	Disposed	10405	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-10-15	Restricted Stock Units	$	M	833	Disposed		Ordinary Shares (833)	Direct
2020-10-15	Restricted Stock Units	$	M	2084	Disposed		Ordinary Shares (2084)	Direct
2020-10-15	Restricted Stock Units	$	M	2000	Disposed		Ordinary Shares (2000)	Direct

Footnotes

F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.

F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.

F3: The reporting person was granted restricted stock units ("RSUs") on January 26, 2019 representing 5,000 ordinary shares. 33.33% of the RSUs vested on January 26, 2020 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F4: The reporting person was granted restricted stock units ("RSUs") on August 20, 2018 representing 5,000 ordinary shares. 33.33% of the RSUs vested on August 20, 2019 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.

F5: The reporting person was granted restricted stock units ("RSUs") on January 31, 2020 representing 5,000 ordinary shares. Under the original terms of the agreement, 33.33% of the RSUs will vest on January 31, 2021 and 8.33% of the remaining RSUs vest in equal quarterly installments thereafter. In September the award was modified to accelerate vesting at October 15, 2020 for amounts of RSUs that would have otherwise become vested as of April 15, 2021.